Decoding Cancer : Dr. Edgar Engleman, Professor of Pathology, Stanford University

In this episode, I sit down with Dr. Edgar Engleman, a pioneering Pathologist and physician-scientist at Stanford University whose work has shaped the very foundation of cancer immunotherapy. As we face rising global cancer rates, Dr. Engleman shares his insights into the evolving landscape of cancer research and what the numbers really mean—scientifically and socially.

We dive deep into his groundbreaking research on erythropoietin (EPO) and its surprising implications in cancer biology, as well as his continued innovations in using the immune system to fight tumors. Dr. Engleman also opens up about his involvement with Vivo Capital and offers candid thoughts on the role of venture capital in bridging science and real-world impact.

No conversation about the future of medicine is complete without exploring AI. Dr. Engleman shares his perspective on how artificial intelligence is beginning to transform cancer detection and prediction, and how it might reshape diagnostics, treatment decisions, and even drug development.

But what strikes me most is Dr. Engleman’s enduring optimism—rooted in decades of scientific rigor. Despite the challenges, he remains steadfast in his belief that with a science-backed, collaborative approach, curing cancer is not just a dream—it’s a destination. This episode is a masterclass in science, hope, and what it means to pursue truth in medicine.

About

Dr. Edgar G. Engleman, MD, PhD, is a renowned pathologist and physician-scientist who serves as Professor of Pathology and of Medicine (Immunology & Rheumatology) at Stanford University School of Medicine. He received his BA magna cum laude from Harvard in 1967 and his MD from Columbia University in 1971. Following postdoctoral training in biochemistry at the NIH and immunogenetics at Stanford, he joined the Stanford faculty in 1978 and earned tenure in 1990. Dr. Engleman founded the Stanford Blood Center in 1980 and continues to serve as its Medical Director. He also co-directs the Tumor Immunology & Immunotherapy Program at the Stanford Cancer Institute and is affiliated with several interdisciplinary research centers, including Bio-X, the Diabetes Research Center, and the Neurosciences Institute.

Dr. Engleman’s research has made pioneering contributions to the field of cancer immunotherapy. His laboratory was the first to isolate and engineer dendritic cells to stimulate anti-tumor immune responses, work that led to the development of Sipuleucel-T (Provenge), the first FDA-approved active immunotherapy for cancer. His recent work focuses on reprogramming tumor-associated myeloid cells to trigger T-cell responses against cancer, with these approaches now in clinical trials. Beyond oncology, his research explores immune mechanisms in metabolic diseases, neurodegeneration, and transplantation, influencing innovative strategies like radiation-based tolerance induction. Dr. Engleman has mentored over 150 trainees, published more than 300 scientific papers, and teaches a popular course on tumor immunology at Stanford.